Advertisement

Geriatrie-Report

, Volume 14, Issue 3, pp 40–47 | Cite as

Wenn die Knochen brüchig werden

Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen

  • Franca GenestEmail author
  • Lothar Seefried
Zertifizierte Fortbildung
  • 53 Downloads

Zusammenfassung

Vitamin-D-Mangel, Medikamente, Multimorbidität — im Alter häufen sich die Risikofaktoren für osteoporotische Knochenbrüche. Insbesondere für ältere Menschen sind Frakturen ein einschneidendes Erlebnis, dass nicht selten zu Immobilität oder Pflegebedürftigkeit führt. Um ein erhöhtes Risiko frühzeitig zu erkennen und adäquat reagieren zu können, sollte der Hausarzt die richtigen Fragen stellen und die Warnzeichen für drohende Knochenbrüche kennen.

Literatur

  1. 1.
    Jakob F, Seefried L, Schwab M. [Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy]. Der Internist. 2014;55(7):755–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE. Bone mineral density and mortality in elderly men and women: the Rotterdam Study. Bone. 2002;30(4):643–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T, et al. The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt international. 2013;110(4):52–7PubMedPubMedCentralGoogle Scholar
  4. 4.
    Jakob F, Seefried L, Ebert R. [Pathophysiology of bone metabolism]. Der Internist. 2008;49(10):1159–60, 62, 64 passim.PubMedCrossRefGoogle Scholar
  5. 5.
    Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. Journal of cellular biochemistry. 2007;102(5):1130–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 2008;3:457–84.CrossRefGoogle Scholar
  7. 7.
    DVO. Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und bei Männern 2017 [cited 2019 2 May]. Available from: https://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf.
  8. 8.
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Lunt M, O’Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone. 2003;33(4):505–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Eklund F, Nordstrom A, Bjornstig U, Nordstrom P. Bone mass, size and previous fractures as predictors of prospective fractures in an osteoporotic referral population. Bone. 2009;45(4):808–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Franca Genest LS. Süße Knochen brechen leichter. Der Allgemeinarzt 2018;40 (17) Seite 34–8.Google Scholar
  13. 13.
    Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nature reviews Endocrinology. 2017;13(4):208–19.PubMedCrossRefGoogle Scholar
  14. 14.
    Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 2014;123(5):647–9.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Drake MT. unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529–33.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging. 2019;36(4):299–307.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Picca A, Calvani R, Manes-Gravina E, Spaziani L, Landi F, Bernabei R, et al. Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis. Current pharmaceutical design. 2017;23(41):6256–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Wagner P, Chapurlat R, Ecochard R, Szulc P. Low Muscle Strength and Mass Is Associated With the Accelerated Decline of Bone Microarchitecture at the Distal Radius in Older Men: the Prospective STRAMBO Study. J Bone Miner Res. 2018;33(9):1630–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Jain RK, Vokes T. Dual-energy X-ray Absorptiometry. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2017;20(3):291–303.CrossRefGoogle Scholar
  22. 22.
    Lewiecki EM. Bone densitometry and vertebral fracture assessment. Current osteoporosis reports. 2010;8(3):123–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc. 2003;51(11):1533–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40(3):716–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89(11):5477–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Therapeutic advances in chronic disease. 2015;6(4):185–93.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRefGoogle Scholar
  30. 30.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res. 2017;32(7):1481–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Leder BZ. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. JBMR Plus. 2018;2(2):62–8.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019;34(3):419–28.PubMedCrossRefGoogle Scholar
  38. 38.
    McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018;4(1):11–5.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93.PubMedCrossRefGoogle Scholar
  40. 40.
    Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Orthopädische Klinik König-Ludwig-HausLehrstuhl für Orthopädie der Universität WürzburgWürzburgDeutschland

Personalised recommendations